北美紫杉烷市场，按类型（紫杉醇、多西他赛、卡巴他赛）、药物类型（仿制药、品牌药）、剂型（脂质体、纳米颗粒、聚合物胶束、其他）、年龄组（成人、老年人）、应用（乳腺癌、非小细胞肺癌、胰腺癌、卵巢癌、前列腺癌、其他）、最终用户（医院、门诊手术中心、专科诊所、其他）分销渠道（零售、直接招标）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
北美花生市场预计将在2022至2029年的预测期间获得市场增长. 数据桥市场研究分析认为,在2022至2029年的预测期间,市场正在增长,CAGR为7.7%. 生物分类药物治疗的技术进步,加上计算机辅助诊断的应用增加,是预测期间推动生物分类市场增长的其他因素.
然而,与药物相关的高成本和副作用,如血凝块,leucopenia,过敏症,痢疾和体重下降会抑制市场的增长. 关键市场参与者通过伙伴关系和收购等战略联盟,是发展分类市场的机会。
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020 |
|
数量单位 |
收入(百万美元),定价(美元) |
|
覆盖部分 |
按类型(Paclitaxel、Docetaxel和Cabazitaxel)、药物类型(布氏和通式)、配方(Liposomes和Polymeric Micelles 内含税烷、Txanes液凝胶配方、纳诺普粒子配方等)、年龄组(Adults和老年病)、应用(Ovarian Cancer、乳腺癌、前列腺癌、非小细胞肺癌等)、最终用户(医院、门诊手术中心、专科诊所等)、分销渠道(Direct Tender,零售销售) |
|
涵盖国家 |
美国、加拿大、墨西哥 |
|
覆盖的市场玩家 |
Viatris Inc., Sandoz International GmbH (A Novartis Division), Sanofi-aventis U.S. LLC., Hikma PLC, Pfize Inc., Reddy博士实验室有限公司,Taxane保健公司,Bristol-Myers Squibb公司,Fresenius Kabi AG(Fresenius SE & Co. KGaA分公司),SAMYANG HOLDINGS CORPORULING.,Luye Phar Macutications Group, Eleevarvar Therapetics, Huiang 药品有限公司,深圳主要勒克乳制品厂有限公司,Aconome保健公司,Torrent药品有限公司,Pana Biotec,RPG生命科学有限公司,Aureate保健公司,Samarth生命科学Pvt有限公司,C.,Hetro保健有限公司,AqVida Gm,Ingenus制药公司,LC公司等。 |
市场定义
分泌物或分泌物是一类紧密相联的抗肿瘤药剂,有独特的作用机制来作为消化抑制剂,被广泛用于卵巢,乳房,肺,食道,前列腺,膀胱和头部和颈部等癌症的治疗. 三种分类物在临床上被使用,paclitaxel (Taxol:1992), docetaxel (Taxote:1996)和cabazitaxel (Jevtana:2010). Taxanes是抗癌药物,会干扰微管功能,引起线粒体硬化和细胞死亡的变化. Paclitaxel (Taxol)最初被从一棵yew树上隔离出,这是一棵生长速度缓慢的小常绿圆形树. 由于和平克萨斯最初稀缺,多克萨斯克萨斯(英语:Docetaxel (Taxote)),一种由欧洲yew tree Taxus baccata的针头所衍生出的和平克萨斯的半合成类似物被创建. Docetaxel在两个化学位置上与和平克塞尔不同,使其更能溶于水. 卡巴齐克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克
此外,由于慢性病发病率上升,癌症发病率上升,对保健基础设施的投资也增加,所以越来越多地使用分类药物。 这些因素增加了对分类市场的需求,鼓励主要市场参与者通过产品推出、获取、战略和协议实施更新的技术和战略。
市场动态
司机
- 癌症发病率的上升
癌症对美国和全世界的社会有重大影响. 癌症统计描述了大量人群中发生的事情,并提供了癌症给社会所造成负担的时间图. 特克索尔是一种抗肿瘤剂,用于治疗癌症,通过阻止细胞分裂来阻断癌细胞生长,导致细胞死亡.
根据国家癌症研究所(NCI),一项资助的临床试验发现,30%的卵巢癌晚期患者对分类烷治疗反应积极. 在临床实践上,分类烷目前是元静脉乳腺癌的标准疗法. 今天,分类醇被列入了世界卫生组织的基本药物示范清单,这是一种细胞毒性药物,可杀死癌细胞. 它治疗乳腺癌,卵巢癌,非小细胞肺癌,胰腺癌等与艾滋病有关的卡波西沙科马.
- 政府提供的资金和研发投资
尽管治疗类阿片使用和酒精紊乱的药效已经得到确认,但人们发现,通过特殊治疗方案实施分类疗法受到限制。 需要注意资金、组织结构和劳动力资源的具体来源,进行长期投资,使付款与未来潜在受益者保持一致。 毒品开发的可持续性、生产力和耐心影响等问题,过去从来没有,将来也不会仅仅是工业的产物。
政府的资助将带来病人的安全,节省费用. 此外,医院和保健机构将通过与政府组织合作,以更低的价格管理这种治疗。 因此,研究与发展活动的进展以及政府提供的资金可望推动市场增长。
限制
-
与生物分类药物有关的药物的副作用
花生属(学名:Taxanes)是属于一科下的一个属. 花烷类药物(英语:Paclitaxel and docetaxel)被用作化疗剂. 由于正在进行的临床试验、研究、癌症类型、治疗计划类型和药物剂量,预计目前的高成本将显示出未来的下降趋势。 花生素药物对于治疗乳腺癌和前列腺癌最为有效. 然而,已经报告了某些副作用。 所报告的不良并发症或副作用将导致分类药物销售量下降,从而会限制药物的销售。 此外,这将影响参与这一市场的制造商的可靠性,因此,预期会限制市场增长。
机会
-
市场参与者的战略举措
由于及时治疗酒精和类阿片紊乱,美国和欧洲对分类烷市场的需求有所增加. 这些有利因素增加了对分类法的需求并为了实现市场需求,小型和主要市场参与者正在利用各种战略。
主要角色还试图设计出具体战略,如产品推出,收购,审批,扩展,以及伙伴关系,以确保企业的平稳运行,避免风险,并增加市场销售的长期增长.
市场参与者的这些战略举措,包括收购、会议和重点部分产品推出,正在帮助公司增长和改善公司的产品组合,最终带来更多的收入。 因此,市场参与者的这些战略举措为帮助未来增长和推动市场增长提供了机会。
挑战
- 缺乏分类药物治疗所需的熟练专业人员
缺乏或缺乏技术专长将挑战一个地方的恢复和增长步伐。 在一个地方的失业人员往往具备在其他地方短缺的技能。 此外,这一领域的快速技术进步也导致缺乏专门知识。
医保供应(physician support)是一个术语,用来描述在保健系统或劳动力市场工作受过训练的医生人数. 这取决于毕业生人数和该专业的留用率。 医师短缺是全世界许多国家日益关切的问题。
世界卫生组织(卫生组织)估计全球短缺430万医生、护士和其他保健专业人员。 尽管有确凿证据表明药物在降低发病率和死亡率、增加保留治疗以及改善有分类烷的个人的福利方面是有效的,但许多障碍阻碍了更广泛地获得基于分类烷的药物治疗。
此外,技术进步是导致对熟练专业人员的需求增加的另一个方面。 神经科医生报告说,其中心内支助护理需求和障碍严重未得到满足,只有少数人认为自己有能力提供支助护理。 迫切需要对专业人员进行治疗痴呆症的教育并获得现有的辅助护理资源。 缺乏训练有素和经验丰富的专业人员和持续存在的技能差距限制了就业前景和获得高质量工作的机会。 因此,显然,具备足够技能的专业人员正在挑战市场增长。
COVID-19之后对税收市场的影响
COVID-19导致保健专业人员和公众对预防措施的医疗用品需求大幅增加。 这些物品的制造商有机会利用医疗用品需求的增加,确保个人防护设备在市场上的稳定供应。 COVID-19预计会对分类烷市场产生重大影响.
最近的事态发展
- 2022年11月,Viatris Inc.和Biocon Biologics Ltd.宣布由美国推出可互换的生物类似物SEMGLE(英语:Insulin glargine-yfgn)注入,一种品牌产品;由Insulin Glargine(英语:Insulin glargine-yfgn)注入,是一种无品牌产品,帮助控制1型糖尿病的成人和儿科患者和2型糖尿病的成年人的高血糖. 两种生物同样产品都以瓶子和预填笔来取出,可以互换为参考品牌"LANTUS"(insulin glargine),可以在药店柜台取而代之. Viatris致力于改善患者获得可持续、优质和更负担得起的医疗保健的机会。 这有助于该公司增加其产品组合。
- 2022年5月,全球通用和生物同型药物领先的桑多兹宣布美国推出其通用pirfenidone,这是首个与Genentech的Esbriet等同的AB级(完全可替代),用于治疗患有异病性肺纤维化(IPF)的患者. 这种处方口服药通过专科药房立即提供给患者,对符合条件的患者实行0元共同付费方案. 桑多兹将患者放在首位,扩大这种罕见疾病的患者获得通用皮尔芬尼酮的渠道,他们将受益于更廉价但同样有效的治疗。 这有助于公司扩大市场地位和经营.
税收范围和市场规模
税收市场按种类,药品种类,配方,年龄组,应用,最终用户和配送渠道进行分化. 各部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域和目标市场的差异。
按类型
- 平板电脑
- Docetaxel 函数
- 卡巴齐克
根据类型,北美花生市场被分出为和平克赛尔,多塞克赛尔和卡巴齐克赛尔.
通过应用程序
- 肿瘤
- 乳腺癌
- 前列腺癌
- 非小细胞肺癌
- 其它
根据应用情况,北美的分类烷市场被分入卵巢癌,乳腺癌,前列腺癌,非小细胞肺癌等.
按药物类型
- 常规
- 品牌
根据药物类型,北美花生市场被分割成品牌和通用产品.
通过拟订
- 唇膏
- 纳米粒子
- 聚合米细胞
- 其他人员
以配方为基础,北美花生市场被分化为唇膏,纳米粒子,聚合小鼠等.
按年龄组
- 成人
- 老年病
根据年龄组,北美的花生市场分为成人和老年类.
按终端用户
- 医院
- 门诊外科中心
- 专科诊所
- 其他人员
在最终用户的基础上,北美的花生市场分为医院、流动外科中心、专科诊所等。
按发行频道
- 直接投标
- 零售
根据分销渠道,北美花生市场被划分为直接招标,零售.
北美Taxane市场区域分析
对分类烷市场进行了分析,并按照类型、药物类型、配方、年龄组、应用、最终用户和分销渠道提供了市场规模信息。
分类烷市场报告涵盖的国家有:美国,加拿大,墨西哥.
2022年,美国由于主要市场参与者在GDP较高的最大消费市场一带而占据了主导地位. 由于药物治疗技术进步的提高,美国预计会增长.
报告的国家部分还介绍了影响市场的因素和国内市场监管的变化,这些因素和变化影响到市场目前和未来的趋势。 新的销售、替代销售、国家人口统计、管制条例和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。 此外,北美品牌的存在和可得性以及它们由于来自当地和国内品牌的大规模或稀缺竞争而面临的挑战,也考虑了销售渠道的影响,同时对国家数据进行预测分析。
税收市场还为各国医疗保健行业的增长提供了详细的市场分析。 此外,报告还提供详细资料,说明保健服务和治疗情况、监管情景的影响以及有关税收市场的趋势参数。
竞争性景观和税收市场份额分析
税收市场竞争环境提供了竞争对手的详细信息。 详细情况包括:公司概况,公司财务,创收,市场潜力,研发投资,新市场举措,生产场所和设施,公司优势和弱点,产品推出,产品试验管线,产品审批,专利,产品宽度和气息,应用优势,技术命脉曲线等. 上述数据点仅与公司与分类药物有关的重点有关。
在分类市场中交易的主要公司有:Viatris Inc., Sandoz International GmbH (A Novartis Division), Sanofi-aventis U.S. LLC., Hikma Phar Maceutics, Pfizer Inc., Reddy博士的实验室有限公司,Taxane保健,Bristol-Myers Squibb公司,Fresenius Kabi AG(Fresenius SE & Co. KGA的子公司),SAMYANG HOLDINGS CORPOLATION., Luye Pharma Group, Elevar Therapeutics, Huiang 医药有限公司,Shenzhen Main Luck Phar Maceuticals Inc., Agrant C., Aureate C., Aureate C., Samarth生命科学Pvtd., Cipla Inc.,Hero保健有限公司,AqVida Gmb., Ing等。
战略联盟,如兼并、收购和主要市场参与者的协议,将进一步加速分类药物的增长。
市场参与者的合作、产品推出、业务扩展、奖励和承认、合资企业和其他战略正在扩大公司在分类市场中的足迹,这也为组织的利润增长提供了好处。
研究方法
数据收集和基准年分析使用具有大样本规模的数据收集模块。 利用市场统计和连贯一致的模式分析和估计市场数据。 此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组采用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(工业专家)验证。 除此之外,数据模型还包括供应商定位网格,市场时间线分析,市场概况和指南,公司定位网格,公司市场份额分析,计量标准,北美对区域和供应商份额分析. 如有进一步调查,请联系分析师。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 NORTH AMERICA TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 NORTH AMERICA TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 NORTH AMERICA TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 NORTH AMERICA TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 NORTH AMERICA TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 NORTH AMERICA TAXANE MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 U.S. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 U.S. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 U.S. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 U.S. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 U.S. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 U.S. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 U.S. CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 U.S. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 U.S. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 U.S. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 U.S. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 U.S. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.S. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 CANADA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 CANADA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 CANADA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 CANADA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 CANADA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 CANADA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 CANADA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 CANADA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 CANADA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 CANADA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 CANADA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 CANADA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 CANADA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 MEXICO TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 MEXICO TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 MEXICO TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 MEXICO TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 MEXICO PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 MEXICO DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 MEXICO CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 MEXICO TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 MEXICO ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 MEXICO GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 MEXICO TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 MEXICO TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 MEXICO RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TAXANE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE NORTH AMERICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 NORTH AMERICA TAXANE MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 NORTH AMERICA TAXANE MARKET: BY END USER, 2021
FIGURE 37 NORTH AMERICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 NORTH AMERICA TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 NORTH AMERICA TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 NORTH AMERICA TAXANE MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
